Five recent developments in psoriasis

Research finding that serious infections were significantly higher in prevalence among inpatients with psoriasis compared with those without psoriasis was a recent development reported on Healio.com/Dermatology.

Other developments included findings that Taltz was effective treatment for patients with moderate-to-severe plaque psoriasis through week 60, and that patients with psoriasis had prolonged hospital stays compared with patients without the disorder:

Serious infection prevalence higher for inpatients with psoriasis vs. those without

Serious infections were significantly higher in prevalence and increasing in incidence among inpatients in the United States with psoriasis compared with those without psoriasis, according to recently published study results.

Jonathan I. Silverberg

Jonathan I. Silverberg, MD, PhD, MPH, of the department of dermatology, Northwestern University Feinberg School of Medicine, and colleagues conducted a cross-sectional study of the Nationwide Inpatient Sample from 2002 to 2012, containing a representative 20% stratified representative sample of all hospitalizations in the United States. Read more

FDA advisory committee to review biosimilar candidate to Humira

The Arthritis Advisory Committee of the FDA has agreed to review data supporting Amgen’s Biologics License Application for ABP 501, a biosimilar to Humira, according to a press release from Amgen.

The committee is scheduled to review data from studies looking at the efficacy and safety of ABP 501for treating moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid arthritis, according to the release. Read more

Taltz effective through 60 weeks in treating patients with psoriasis

Taltz was effective treatment for patients with moderate-to-severe plaque psoriasis through week 60, according to results from three phase 3 trials recently published in The New England Journal of Medicine.

“This group of studies not only shows very high and consistent levels of safety and efficacy, but also that the great majority of the responses persist at least 60 weeks,” Kenneth B. Gordon, MD, professor of dermatology at Northwestern University Feinberg School of Medicine, stated in a news release. Read more

Kawasaki disease-linked psoriasiform eruptions differ from classic psoriasis

Unlike conventional psoriasis among children, psoriasiform eruptions that developed during Kawasaki disease are a distinct phenotype with a tendency for remission, according to study results.

“Kawasaki disease (KD) is an acute systemic inflammatory illness causing vasculitis and potentially fatal coronary artery aneurysms in 15% to 25% of untreated children,” Ellen S. Haddock, AB, MBA, of the School of Medicine at University of California, San Diego, and colleagues wrote. “A psoriasis-like eruption develops in a small subset of patients during the acute, subacute, or convalescent phases of the disease. Read more

Racial, health care disparities found in hospitalization for psoriasis

Patients with psoriasis had prolonged hospital stays compared with patients without the disorder, and there were significant racial and ethnic, socioeconomic and heath care disparities related to hospitalization for psoriasis, according to recently published study results.

Researchers analyzed the 2002 to 2012 Nationwide Inpatient Sample which contains approximately a 20% representative sample of all hospitalizations in the United States. ICD-9-CM codes were used to determine a primary diagnosis of psoriasis and psoriatic arthritis. Read more